About IRIDEX Corporation (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:IRIX
- CUSIP: N/A
- Web: www.iridex.com
Capitalization:- Market Cap: $110.12 million
- Outstanding Shares: 11,567,000
Average Prices:- 50 Day Moving Avg: $9.48
- 200 Day Moving Avg: $9.48
- 52 Week Range: $7.58 - $16.39
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.88
- P/E Growth: -0.44
Sales & Book Value:- Annual Revenue: $42.8 million
- Price / Sales: 2.57
- Book Value: $3.25 per share
- Price / Book: 2.93
Profitability:- EBITDA: ($5,810,000.00)
- Net Margins: -37.62%
- Return on Equity: -16.87%
- Return on Assets: -13.86%
Debt:- Current Ratio: 5.61%
- Quick Ratio: 4.15%
Misc:- Average Volume: 28,615 shs.
- Beta: 1.29
- Short Ratio: 4.92
Frequently Asked Questions for IRIDEX Corporation (NASDAQ:IRIX)
What is IRIDEX Corporation's stock symbol?
IRIDEX Corporation trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX Corporation's earnings last quarter?
IRIDEX Corporation (NASDAQ:IRIX) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.06. The firm earned $10 million during the quarter, compared to the consensus estimate of $10.48 million. IRIDEX Corporation had a negative net margin of 37.62% and a negative return on equity of 16.87%. View IRIDEX Corporation's Earnings History.
When will IRIDEX Corporation make its next earnings announcement?
Where is IRIDEX Corporation's stock going? Where will IRIDEX Corporation's stock price be in 2017?
1 analysts have issued 12-month target prices for IRIDEX Corporation's shares. Their predictions range from $20.00 to $20.00. On average, they anticipate IRIDEX Corporation's share price to reach $20.00 in the next year. View Analyst Ratings for IRIDEX Corporation.
Who are some of IRIDEX Corporation's key competitors?
Some companies that are related to IRIDEX Corporation include Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Neovasc (NVCN), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Fulgent Genetic (FLGT), Electromed (ELMD), Biolase (BIOL), Invivo Therapeutics Holdings Corp (NVIV), Digirad Corporation (DRAD), Luna Innovations Incorporated (LUNA), Advanced Oncotherapy PLC (AVO), EnteroMedics (ETRM), Xtant Medical Holdings (XTNT) and Dynatronics Corporation (DYNT).
Who are IRIDEX Corporation's key executives?
IRIDEX Corporation's management team includes the folowing people:
- William M. Moore Jr., Chairman of the Board, Interim President and Chief Executive Officer
- Atabak Mokari, Chief Financial Officer, Vice President - Corporate Development
- George R. Marcellino PhD, Director
- Ann D. Rhoads, Director
- Sanford Fitch, Independent Director
- Ruediger Naumann-Etienne Ph.D., Independent Director
Who owns IRIDEX Corporation stock?
IRIDEX Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Osborne Partners Capital Management LLC (0.62%) and Ingalls & Snyder LLC (0.22%). Company insiders that own IRIDEX Corporation stock include George R Marcellino, Romeo R Dizon, Ronald Steckel, Ruediger Naumann-Etienne and William M Moore. View Institutional Ownership Trends for IRIDEX Corporation.
Who bought IRIDEX Corporation stock? Who is buying IRIDEX Corporation stock?
How do I buy IRIDEX Corporation stock?
Shares of IRIDEX Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRIDEX Corporation's stock price today?
One share of IRIDEX Corporation stock can currently be purchased for approximately $9.52.
MarketBeat Community Rating for IRIDEX Corporation (NASDAQ IRIX)MarketBeat's community ratings are surveys of what our community members think about IRIDEX Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for IRIDEX Corporation (NASDAQ:IRIX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $20.00 (110.08% upside) |
Consensus Price Target History for IRIDEX Corporation (NASDAQ:IRIX)
Analysts' Ratings History for IRIDEX Corporation (NASDAQ:IRIX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 12/21/2016 | Roth Capital | Initiated Coverage | Buy | $20.00 | N/A |  |
| 1/26/2016 | Singular Research | Initiated Coverage | Buy | $11.50 | N/A | |
(Data available from 10/22/2015 forward)
Earnings History for IRIDEX Corporation (NASDAQ:IRIX)Earnings History by Quarter for IRIDEX Corporation (NASDAQ IRIX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | ($0.28) | | | | | N/A | |
| 8/3/2017 | Q2 2017 | ($0.18) | ($0.24) | $10.48 million | $10.00 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.18) | ($0.16) | $10.62 million | $10.48 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.03) | ($0.07) | $11.20 million | $9.79 million | View | Listen | |
| 8/4/2016 | Q216 | $0.01 | ($0.03) | $11.90 million | $11.90 million | View | Listen | |
| 5/5/2016 | Q116 | $0.04 | $0.01 | $11.88 million | $11.90 million | View | Listen | |
| 3/3/2016 | Q415 | $0.04 | $0.04 | $11.80 million | $12.10 million | View | Listen | |
| 11/5/2015 | Q315 | | $0.04 | $10.10 million | $9.80 million | View | Listen | |
| 8/6/2015 | Q215 | | ($0.07) | $10.60 million | $9.00 million | View | Listen | |
| 5/7/2015 | Q115 | | $0.02 | $10.30 million | $10.80 million | View | Listen | |
| 5/1/2014 | Q1 | $0.06 | $0.05 | $8.90 million | $10.30 million | View | Listen | |
| 2/27/2014 | Q4 | $0.04 | $0.04 | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for IRIDEX Corporation (NASDAQ:IRIX)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.18) | ($0.18) | ($0.18) |
| Q2 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for IRIDEX Corporation (NASDAQ:IRIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for IRIDEX Corporation (NASDAQ:IRIX)Insider Ownership Percentage: 5.01%
Institutional Ownership Percentage: 47.46%
Insider Trades by Quarter for IRIDEX Corporation (NASDAQ:IRIX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | William M Moore | Chairman | Buy | 1,800 | $9.42 | $16,956.00 | |
| 3/15/2017 | Romeo R Dizon | Insider | Sell | 2,811 | $13.16 | $36,992.76 | |
| 11/16/2016 | Romeo R Dizon | Insider | Sell | 584 | $16.04 | $9,367.36 | |
| 9/12/2016 | Romeo R Dizon | Insider | Sell | 125 | $15.00 | $1,875.00 | |
| 9/7/2016 | Ruediger Naumann-Etienne | Director | Sell | 9,513 | $14.75 | $140,316.75 | |
| 9/2/2016 | Ruediger Naumann-Etienne | Director | Sell | 2,513 | $14.73 | $37,016.49 | |
| 8/23/2016 | Romeo R Dizon | Insider | Sell | 875 | $14.52 | $12,705.00 | |
| 8/19/2016 | Romeo R Dizon | Insider | Sell | 7,896 | $13.52 | $106,753.92 | |
| 8/16/2016 | George R Marcellino | Director | Sell | 2,513 | $13.57 | $34,101.41 | |
| 8/16/2016 | Romeo R Dizon | Insider | Sell | 839 | $13.70 | $11,494.30 | |
| 6/6/2016 | Ronald Steckel | VP | Sell | 625 | $13.52 | $8,450.00 | |
| 5/17/2016 | Ronald Steckel | VP | Sell | 4,583 | $12.81 | $58,708.23 | |
| 3/8/2016 | Ronald Steckel | VP | Sell | 12,000 | $10.45 | $125,400.00 | |
| 11/19/2015 | William M Moore | CEO | Buy | 10,000 | $9.83 | $98,300.00 | |
| 9/25/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 52,042 | $7.05 | $366,896.10 | |
| 9/10/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 11,866 | $6.95 | $82,468.70 | |
| 9/4/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 10,304 | $6.81 | $70,170.24 | |
| 9/2/2015 | Ronald Steckel | VP | Sell | 1,875 | $6.80 | $12,750.00 | |
| 8/21/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 20,651 | $7.16 | $147,861.16 | |
| 8/19/2015 | James H. Mackaness | CFO | Sell | 2,373 | $7.15 | $16,966.95 | |
| 8/19/2015 | Ronald Steckel | VP | Sell | 1,751 | $7.14 | $12,502.14 | |
| 8/18/2015 | James H. Mackaness | CFO | Sell | 2,627 | $7.10 | $18,651.70 | |
| 8/17/2015 | James H. Mackaness | CFO | Sell | 2,235 | $7.05 | $15,756.75 | |
| 8/14/2015 | James H Mackaness | CFO | Sell | 7,765 | $6.99 | $54,277.35 | |
| 8/14/2015 | Ronald Steckel | VP | Sell | 1,458 | $7.00 | $10,206.00 | |
| 7/24/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 40,403 | $7.01 | $283,225.03 | |
| 6/17/2015 | Ronald Steckel | VP | Sell | 1,666 | $8.77 | $14,610.82 | |
| 5/20/2015 | James H Mackaness | CFO | Sell | 2,000 | $9.80 | $19,600.00 | |
| 5/18/2015 | Ronald Steckel | VP | Sell | 1,667 | $9.33 | $15,553.11 | |
| 4/20/2015 | Ronald Steckel | VP | Sell | 1,447 | $9.79 | $14,166.13 | |
| 4/17/2015 | Ronald Steckel | VP | Sell | 1,667 | $9.86 | $16,436.62 | |
| 3/17/2015 | Ronald Steckel | VP | Sell | 11,358 | $10.08 | $114,488.64 | |
| 3/10/2015 | Ronald Steckel | VP | Sell | 1,250 | $10.03 | $12,537.50 | |
| 2/17/2015 | Ronald Steckel | VP | Sell | 1,650 | $9.79 | $16,153.50 | |
| 1/20/2015 | Ronald Steckel | VP | Sell | 1,650 | $9.03 | $14,899.50 | |
| 12/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.52 | $14,058.00 | |
| 11/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.28 | $13,662.00 | |
| 11/6/2014 | William M Moore | Director | Buy | 5,000 | $7.79 | $38,950.00 | |
| 10/12/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 17,237 | $8.11 | $139,792.07 | |
| 10/10/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 12,798 | $8.02 | $102,639.96 | |
| 9/5/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 8,432 | $7.99 | $67,371.68 | |
| 8/29/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 4,272 | $7.92 | $33,834.24 | |
| 8/22/2014 | James B Hawkins | Director | Sell | 600 | $8.03 | $4,818.00 | |
| 8/18/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.00 | $13,200.00 | |
| 8/15/2014 | James B Hawkins | Director | Sell | 14,400 | $8.10 | $116,640.00 | |
| 8/14/2014 | James B Hawkins | Director | Sell | 2,714 | $8.08 | $21,929.12 | |
| 8/13/2014 | James B Hawkins | Director | Sell | 9,786 | $8.11 | $79,364.46 | |
| 8/11/2014 | Garrett A Garrettson | Director | Sell | 2,810 | $8.30 | $23,323.00 | |
| 7/31/2014 | Ronald Steckel | VP | Sell | 761 | $8.00 | $6,088.00 | |
| 7/21/2014 | James H Mackaness | CFO | Sell | 1,000 | $7.62 | $7,620.00 | |
| 6/23/2014 | James H Mackaness | CFO | Sell | 2,000 | $8.24 | $16,480.00 | |
| 6/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.20 | $13,530.00 | |
| 6/6/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 7,390 | $8.32 | $61,484.80 | |
| 6/3/2014 | William M Moore | CEO | Buy | 5,000 | $8.48 | $42,400.00 | |
| 5/21/2014 | James H Mackaness | CFO | Sell | 3,000 | $8.73 | $26,190.00 | |
| 5/19/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.82 | $14,553.00 | |
| 5/9/2014 | William M Moore | CEO | Buy | 5,000 | $8.40 | $42,000.00 | |
| 4/22/2014 | James H Mackaness | CFO | Sell | 4,000 | $8.74 | $34,960.00 | |
| 4/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.88 | $14,652.00 | |
| 3/21/2014 | James H Mackaness | CFO | Sell | 4,000 | $9.03 | $36,120.00 | |
| 3/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $9.07 | $14,965.50 | |
| 2/18/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.60 | $14,190.00 | |
| 1/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $10.42 | $17,193.00 | |
| 12/17/2013 | Ronald Steckel | VP | Sell | 1,650 | $8.56 | $14,124.00 | |
| 12/2/2013 | James H Mackaness | CFO | Sell | 10,000 | $10.52 | $105,200.00 | |
| 9/6/2013 | Ruediger Naumann-Etienne | Director | Buy | 3,600 | $5.99 | $21,564.00 | |
| 8/9/2013 | William M Moore | CEO | Buy | 10,000 | $5.88 | $58,800.00 | |
| 6/19/2013 | Eduardo Arias | VP | Sell | 22,768 | $5.43 | $123,630.24 | |
| 6/18/2013 | James H Mackaness | CFO | Sell | 19,862 | $4.58 | $90,967.96 | |
| 6/17/2013 | Eduardo Arias | VP | Sell | 4,532 | $5.39 | $24,427.48 | |
| 6/14/2013 | James H Mackaness | CFO | Sell | 10,568 | $5.38 | $56,855.84 | |
| 6/13/2013 | James H Mackaness | CFO | Sell | 1,400 | $5.30 | $7,420.00 | |
| 6/11/2013 | Eduardo Arias | VP | Sell | 1,000 | $5.61 | $5,610.00 | |
| 6/11/2013 | James H Mackaness | CFO | Sell | 1,200 | $5.61 | $6,732.00 | |
| 6/10/2013 | Eduardo Arias | VP | Sell | 2,400 | $5.38 | $12,912.00 | |
| 6/10/2013 | James H Mackaness | CFO | Sell | 6,970 | $5.36 | $37,359.20 | |
| 6/6/2013 | William M Moore | CEO | Buy | 2,000 | $5.42 | $10,840.00 | |
| 5/17/2013 | Eduardo Arias | VP | Sell | 10,000 | $6.30 | $63,000.00 | |
| 3/8/2013 | Ruediger Naumann-Etienne | Director | Buy | 2,400 | $4.80 | $11,520.00 | |
| 3/7/2013 | William M Moore | CEO | Buy | 10,000 | $4.66 | $46,600.00 | |
| 9/6/2012 | William M Moore | CEO | Buy | 10,000 | $3.76 | $37,600.00 | |
| 8/15/2012 | Catalyst Fund Ix L.P Blueline | Major Shareholder | Buy | 60,900 | $3.19 | $194,271.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for IRIDEX Corporation (NASDAQ:IRIX)
Latest Headlines for IRIDEX Corporation (NASDAQ:IRIX)
| Source: |
|
Loading headlines, please wait.
IRIDEX Corporation (IRIX) Chart for Sunday, October, 22, 2017
